Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability and Quality of Life

BACKGROUND: Low-contrast visual acuity (LCVA), a sensitive measure of visual function in multiple sclerosis (MS), demonstrated treatment effects as a secondary outcome measure in the Phase 3 trial of natalizumab, AFFIRM. In these posttrial analyses, we studied the relation of visual function to qual...

Descripción completa

Detalles Bibliográficos
Autores principales: Chahin, Salim, Balcer, Laura J., Miller, Deborah M., Zhang, Annie, Galetta, Steven L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Neuro-Ophthalmology 2015
Materias:
Original Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337583/
https://www.ncbi.nlm.nih.gov/pubmed/25370598
http://dx.doi.org/10.1097/WNO.0000000000000173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337583/
https://www.ncbi.nlm.nih.gov/pubmed/25370598
http://dx.doi.org/10.1097/WNO.0000000000000173

Ejemplares similares